The first efforts in investigating blood samples of NB patients showed that high levels of circulating tyrosine hydroxylase (TH), PHOX2B, and doublecortin (DCX) mRNAs in peripheral blood (PB) and bone marrow (BM) samples at diagnosis are indicative of poor treatment response and worse clinical outcome [90]. The gene discussed is DCX; the disease is neuroblastoma.